Erastin

CAS No. 571203-78-6

Erastin( Erastin )

Catalog No. M15083 CAS No. 571203-78-6

Erastin is a ferroptosis activator by acting on mitochondrial VDAC, exhibiting selectivity for tumor cells bearing oncogenic RAS.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 87 In Stock
10MG 122 In Stock
25MG 206 In Stock
50MG 311 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Erastin
  • Note
    Research use only, not for human use.
  • Brief Description
    Erastin is a ferroptosis activator by acting on mitochondrial VDAC, exhibiting selectivity for tumor cells bearing oncogenic RAS.
  • Description
    Erastin is a ferroptosis activator by acting on mitochondrial VDAC, exhibiting selectivity for tumor cells bearing oncogenic RAS.(In Vitro):Erastin (10 μM; 24 h) triggers ferroptosis in ectopic endometrial stromal cells (EESCs), and increases the total ROS level at 9 h.Erastin shorts mitochondria and increases membrane density in EESCs.Erastin (10 μM; 9 h) decreases the mRNA expression levels of iron-related proteins, such FPN (iron exporter) in EESCs. However, FPN overexpression significantly inhibits erastin-induced ferroptosis in EESCs.Erastin (10 μM; 24 h) induces mitochondrial permeability transition pore (mPTP) opening in HT-29 colorectal cancer cells.Erastin (30 μM; 72 h) significantly inhibits the growth of HT-29 colorectal cancer cells.The molecular mechanism by which Erastin induces ferroptosis is related to genes regulating iron or mitochondrial fatty acid metabolism. Includes ribosomal protein L8, iron response element binding protein 2 (IREB2), ATP synthase F0 complex subunit C3, citrate synthase, tetrapeptide repeat domain 35, and acyl-CoA synthetase family member 2 (ACSF2).(In Vivo):Erastin (40 mg/kg; i.p.; once every 3 days for 2 weeks) suppresses endometriotic implants in the mouse endometriosis model, indicating Erastin regresses ectopic lesions by trigging ferroptosis.Erastin (10 mg/kg, 30 mg/kg; i.p.; once daily.
  • In Vitro
    Cell Viability Assay Cell Line:Normal endometrial stromal cells (NESCs) and endometrial stromal cells (EESCs)Concentration:0, 0.5, 0.8, 1, 1.5, 2, 2.5, 5, 10?μM Incubation Time:24 hours Result:Induced cell detachment and overt death in EESCs, but not NESCs.Apoptosis AnalysisCell Line:EESCs infected with adenovirus expressing FPN cDNA (co-incubation for 24 hr)Concentration:0, 0.5, 1.5, 2.5, 5 and 2.5?μM Incubation Time:24 hours Result:Induced ferroptosis by decreasing the levels of total ROS and lipid ROS. And reversed by the overexpression of FPN in adenovirus-infected cells.
  • In Vivo
    Animal Model:Mouse model of endometriosisDosage:40 mg/kg Administration:Intraperitoneal injection; once every 3 days for 2 weeksResult:Showed little impact on body weight of mice and hair of mice displayed neat and glossy.
  • Synonyms
    Erastin
  • Pathway
    Apoptosis
  • Target
    Ferroptosis
  • Recptor
    Ferroptosis
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    571203-78-6
  • Formula Weight
    547.04
  • Molecular Formula
    C30H31ClN4O4
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 19 mg/mL (34.73 mM)
  • SMILES
    O=C1N(C2=CC=CC=C2OCC)C(C(N3CCN(C(COC4=CC=C(Cl)C=C4)=O)CC3)C)=NC5=C1C=CC=C5
  • Chemical Name
    2-(1-(4-(2-(4-chlorophenoxy)acetyl)piperazin-1-yl)ethyl)-3-(2-ethoxyphenyl)quinazolin-4(3H)-one

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Dolma S, et al. Y Cell. 2003, 3(3), 285-296.
molnova catalog
related products
  • UAMC-3203

    UAMC-3203 is a novel potent, drug-like ferroptosis inhibitor with IC50 of 12 nM.

  • ROS-generating?agent...

    Ros-generating agent 1 has anticancer activity and generates ROS by covalently modifying Sec-498 residues of TrxR.

  • Ferrostatin-1

    Ferrostatin-1 is a potent ferroptosis inhibitor with IC50 of 33 nM.